- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02904785
Extracorporeal Focused Shock Wave Therapy for Primary Knee Osteoarthritis
The Efficacy of Extracorporeal Focused Shock Wave Therapy for Patients With Primary Knee Osteoarthritis
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This study is a placebo controlled Randomized Clinical Trial (RCT) in which the primary outcome is to determine whether Extracorporeal Focused Shock Wave Therapy (ESWT) reduces knee pain comparing the VAS at baseline and one month after the end of the treatment. Function assessment and progression of pain along the treatment are the secondary outcomes. Function will be assessed with the Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC), the Lequesne's Algofunctional Questionnaire for Osteoarthritis of Knee (Lequesne) and the Timed up and Go (TUG).
The ESWT applications will be performed once a week for four consecutive weeks, the patients will be assessed for pain and function before the beginning of the treatment and one week after every application of the ESWT.
The treatment groups will be randomized. The allocation of the patients is sealed and will not be disclosed to the patients nor to the evaluators.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Sao Paulo, Brasil, 04116-030
- Reclutamiento
- Centro de Pesquisa Clínica do Instituto de Medicina Física e Reabilitação do HCFMUSP
-
Contacto:
- Fabíola Cavalieri, MD
- Número de teléfono: 55-11-99212-3999
- Correo electrónico: fabiola.cavalieri@hc.fm.usp.br
-
Contacto:
- Artur C Santos
- Número de teléfono: 55-11-5180-7897
- Correo electrónico: artur.santos@hc.fm.usp.br
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Clinical and radiologic diagnosis of primary knee osteoarthritis (Kellgren & Lawrence I, II or III);
- Capability to understand the Informed Consent Form;
- Chronic pain for at least 3 months prior to inclusion, measured by VAS. (VAS 4 or above);
- Absence of skin injures, infections or tumor in the target knee;
- Availability to comply with the visits.
Exclusion Criteria:
- History of spinal cord stenosis or clinical symptoms of lumbar radiculopathy;
- History or onset neurological diseases;
- Generalized pain or fibromyalgia;
- Inability to walk;
- History of knee surgery in the target knee;
- Secondary causes of osteoarthritis;
- Use of statins and quinolones in the previous year;
- Uncontrolled and ongoing psychiatric diseases;
- Invasive knee treatments with hyaluronic acid infusion, corticosteroids and anaesthetics, in the target knee, up to 6 months previous to study inclusion.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Extracorporeal Shock Waves
Focused shock waves delivered by an electromagnetic generator with a focus of 5.0cm deep on the affected knee in three different positions.
A total of 7000 pulses will be delivered on a weekly session for four weeks.
|
Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
|
|
Comparador falso: Sham Extracorporeal Shock Waves
Sham focused shock waves delivered by an electromagnetic generator on the affected knee in three different positions.
A total of 7000 pulses will be delivered on a weekly session for four weeks.
A foam will be placed in the probe as to stop the energy to be transmitted to the patient's knee, so no focused shockwaves will be delivered.
|
Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Knee Pain after one month
Periodo de tiempo: One month
|
Mean change in Visual Analogue Scale (VAS) score one month after the end of the treatment compared to baseline.
|
One month
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Knee pain progression
Periodo de tiempo: One week after each of four weekly ESWT applications
|
Mean change in VAS score one week after each application compared to baseline.
|
One week after each of four weekly ESWT applications
|
|
Knee Pain after three months
Periodo de tiempo: Three months
|
Mean change in VAS score three months after the end of the treatment compared to baseline.
|
Three months
|
|
Lequesne Knee Function progression
Periodo de tiempo: One week after each of four weekly ESWT applications
|
Mean change in Lequesne score one week after each application compared to baseline.
|
One week after each of four weekly ESWT applications
|
|
Lequesne Knee Function after three months
Periodo de tiempo: Three months
|
Mean change in Lequesne three months after the end of the treatment compared to baseline.
|
Three months
|
|
WOMAC Knee Function progression
Periodo de tiempo: One week after each of four weekly ESWT applications
|
Mean change in WOMAC score one week after each application compared to baseline.
|
One week after each of four weekly ESWT applications
|
|
TUG Knee Function progression
Periodo de tiempo: One week after each of four weekly ESWT applications
|
Mean change in TUG score one week after each application compared to baseline.
|
One week after each of four weekly ESWT applications
|
|
WOMAC Knee Function after three months
Periodo de tiempo: Three months
|
Mean change in WOMAC score three months after the end of the treatment compared to baseline.
|
Three months
|
|
TUG Knee Function after three months
Periodo de tiempo: Three months
|
Mean change in TUG score three months after the end of the treatment compared to baseline.
|
Three months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Linamara R Battistella, PhD, MD, University of Sao Paulo
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 54013616.1.0000.0068
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .